Clinical efficacy of osimertinib combined with nimotuzumab in first-line treatment of advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation
Objective To investigate the clinical efficacy of osimertinib combined with nimotuzumab in first-line treatment of advanced non-small cell lung cancer(NSCLC)patients with epidermal growth factor receptor(EGFR)muta-tion.Method According to different treatment methods,160 patients with EGFR mutant advanced NSCLC were divided into observation group and control group,with 80 cases in each group.Patients in the control group were treated with osimertinib,while patients in the observation group were treated with osimertinib combined with nimotuzumab.The clini-cal efficacy,serum tumor markers[carcinoembryonic antigen(CEA),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125)]levels,serum growth factors[insulin-like growth factor-1(IGF-1),vascular endo-thelial growth factor(VEGF)]levels,incidence of adverse reactions,and survival status of 1-year follow up were com-pared between the two groups.Result After 3 months of treatment,the total effective rate of the observation group was 57.50%,which was higher than 38.75%of the control group,and the difference was statistically significant(P<0.05).Af-ter treatment,the serum levels of CEA,CYFRA21-1,CA125,VEGF,and IGF-1 in both groups were lower than those be-fore treatment,the levels of CEA,CYFRA21-1,CA125,VEGF,and IGF-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There were no statistically signifi-cant differences in the incidence of diarrhea,nausea and vomiting,rash,liver function damage,and kidney function dam-age between the two groups(P>0.05).The 1-year survival rate of patients in the observation group was 96.25%,which was higher than 78.75%in the control group,and the difference was statistically significant(P<0.05).Conclusion Osimertinib combined with nimotuzumab in first-line treatment of EGFR mutant advanced NSCLC shows significant effi-cacy,which can reduce tumor marker and growth factor levels and improve prognosis,with good safety.
NETL
NSTL
万方数据
